18th May 2022 | Pharma Updates
Aurobindo Pharma's Unit-VII receives six FDA observations
USFDA issued Aurobindo’s Unit 7 official action indicated status in 2020. As per US FDA observations, Aurobindo Pharma’s Unit 7 facilities do not follow written procedures for production or process controls.
Takeda launched Adynovate, a haemophilia drug in India
Takeda Pharmaceutical Company Limited has launched Adynovate, an extended half-life recombinant Factor VIII (rFVIII) treatment for haemophilia A patients that uses proven technology (controlled PEGylation).
Greek government is planning to file a lawsuit Novartis for bribery
The Greek health ministry is preparing legal documents to seek compensation from Novartis for allegedly bribing former government officials and healthcare providers to ensure the sale of its medicines in the country.
GlaxoSmithKline Pharma reports consolidated net loss of Rs 55 crore
GlaxoSmithKline Pharmaceuticals reported a consolidated net loss of Rs 55 crore from continuing operations for the March quarter on Monday (Q4FY22). The pharmaceutical company reported a net profit of Rs 4 crore for the fourth fiscal quarter of FY21.
FDA Approves an Early Alzheimer's Disease Detection Test
By testing cerebral spinal fluid, a new tool will be available to improve the early detection of Alzheimer’s disease. FDA recently approved the first in vitro diagnostic test for the early detection of amyloid plaques in Alzheimer’s disease patients.
Goldman Sachs expected to invest Rs 2,700 crore in PharmEasy's parent company
Goldman Sachs is in advanced talks to invest $350 million (Rs 2,700 crore) in API Holdings Ltd, the parent company of online pharmacy PharmEasy, in a structured debt transaction.
AstraZeneca expands its COVID portfolio with the acquisition of RQ Bio
AstraZeneca decided to expand its COVID-19 antibody portfolio on Tuesday with a $157 million licencing agreement for experimental therapies developed by newly launched biotech RQ Bio.
FDA approved a Pfizer-BioNTech booster shot for children aged 5 and older
Booster doses of the Pfizer-BioNTech COVID-19 vaccine have been approved by the USFDA for children aged 5 to 11 and receive a third dose of the vaccine after receiving the first two doses from Pfizer BioNTech.